7WQ-27186-42003
3 vaccinations
4 coded responses
32 check-ins
4 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 66+
- ZIP prefix
- 875 / NM
- Registered
- 2021-01-28
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-27
Dose 1 — Pfizer-BioNTech
-
2021-01-28
Registered in v-safe
-
2021-01-29
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-01-31
- 2021-02-01
- 2021-02-02
- 2021-02-05
- 2021-02-10
-
2021-02-17
Dose 2 — Pfizer-BioNTech
- 2021-02-17
- 2021-02-18
- 2021-02-19
- 2021-02-20
- 2021-02-21
- 2021-02-22
-
2021-02-24
Survey response — day 7, dose 2MedDRA: Fatigue — Feeling: Good · Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: On day 5 I had fatigue and tiredness and slept much of the dayMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-03
- 2021-03-10
- 2021-03-17
- 2021-03-24
- 2021-03-31
- 2021-05-19
-
2021-08-18
Dose 3 — Pfizer-BioNTech
- 2021-08-20
-
2021-08-20
Survey response — days 1–6 daily, dose 3MedDRA: Dyspnoea paroxysmal nocturnal, Headache, Immediate post-injection reaction — Feeling: Good · Site: PainFree text: HA day 2; minimal increased PND 15 min after injection lasting 15 minMedDRA releases: 2021-09,2024-11 · check-in free text available
- 2021-08-22
- 2021-08-23
- 2021-08-24
- 2021-08-25
-
2021-09-01
Survey response — day 14, dose 3MedDRA: Headache, Malaise, Rhinorrhoea — Feeling: Good · Be unable to do your normal daily activitiesFree text: Around day 12 after the injection I woke up with a frontal headache, slight, runny nose and malaise. The symptoms lasted a few hours and then went away. The symptoms were significant enough that I canceled a lunch date that Sunday and golf the next dMedDRA releases: 2021-09,2024-11 · check-in free text available
- 2021-09-08
- 2021-09-15
- 2021-09-24
- 2021-11-17
- 2022-02-16
-
2022-08-20
Survey response — 12 months, dose 3MedDRA: Antibody test positive, COVID-19, Supraventricular tachycardia — Feeling: Good · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: I had COVID on May 14, 2022 and took Paxlovid. My rapid antibody test was positive for 21 days. I experienced some SVT a few weeks later.MedDRA releases: 2024-11 · check-in free text available
-
2022-08-20
Report sent to call center — 12 months, dose 3Be unable to work or attend school · Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-08-22
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-27 | Pfizer-BioNTech | |
| 2 | 2021-02-17 | Pfizer-BioNTech | |
| 3 | 2021-08-18 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 4 — day 7, dose 2
Systemic reaction (other): On day 5 I had fatigue and tiredness and slept much of the day
Release 9 — days 1–6 daily, dose 3
Systemic reaction (other): HA day 2; minimal increased PND 15 min after injection lasting 15 min
Release 9 — day 14, dose 3
Symptoms: Around day 12 after the injection I woke up with a frontal headache, slight, runny nose and malaise. The symptoms lasted a few hours and then went away. The symptoms were significant enough that I canceled a lunch date that Sunday and golf the next d cut off by CDC
Release 12 — 12 months, dose 3
Symptoms: I had COVID on May 14, 2022 and took Paxlovid. My rapid antibody test was positive for 21 days. I experienced some SVT a few weeks later.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Antibody test positive | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Headache | ✓ | · | ✓ |
| SD | Malaise | ✓ | · | ✓ |
| SD | Rhinorrhoea | ✓ | · | ✓ |
| SD | Supraventricular tachycardia | · | · | ✓ |
| SRO | Dyspnoea paroxysmal nocturnal | ✓ | · | ✓ |
| SRO | Fatigue | ✓ | ✓ | ✓ |
| SRO | Headache | ✓ | · | ✓ |
| SRO | Immediate post-injection reaction | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release